What is Parse Biosciences?
Headquartered in Seattle, Parse Biosciences is a global life sciences enterprise dedicated to developing scalable, accessible single-cell sequencing solutions. By eliminating the requirement for specialized, high-cost instrumentation, the company empowers researchers to conduct sophisticated transcriptomic and immune profiling. Its core technology, the Evercode platform, serves as a critical catalyst for breakthroughs in diverse fields, including oncology, stem cell therapy, and immunology. By lowering the barrier to entry for high-throughput sequencing, Parse Biosciences is effectively decentralizing genomic research, enabling labs worldwide to accelerate discoveries that directly impact human health and biological understanding.
How much funding has Parse Biosciences raised?
Parse Biosciences has raised a total of $98.5M across 3 funding rounds:
Other Financing Round
$7M
Series B
$41.5M
Series C
$50M
Other Financing Round (2021): $7M with participation from Bioeconomy Capital
Series B (2022): $41.5M led by Logos Capital, Marshall Wace, Janus Henderson Investors, Soleus Capital, and Bioeconomy Capital
Series C (2023): $50M supported by Janus Henderson Investors, Soleus Capital, Sahsen Ventures, Marshall Wace, Saras Capital, and Bioeconomy Capital
Key Investors in Parse Biosciences
Janus Henderson Investors
A global investment management firm providing disciplined investment solutions and advisory services to institutional and professional clients through in-depth research.
Soleus Capital
A healthcare-focused investment firm specializing in innovative life sciences sectors, including biotech, medtech, and genomics, across the entire corporate lifecycle.
Bioeconomy Capital
An early-stage venture capital firm dedicated to the bioeconomy, focusing on technologies that enable biological engineering and production.
What's next for Parse Biosciences?
With the successful closure of its latest financing round, Parse Biosciences is well-positioned to transition from a high-growth innovator to a dominant market player in the genomics space. The strategic deployment of this capital will likely focus on expanding the commercial footprint of the Evercode platform, enhancing its suite of analytical tools, and deepening partnerships with global research institutions. As the demand for accessible, high-resolution cellular data continues to surge, the company is poised to capture significant market share by addressing the critical need for cost-effective, scalable sequencing solutions in both academic and clinical settings. Future growth will likely be defined by the continued integration of its technology into standard laboratory workflows, further cementing its role as an essential infrastructure provider for the next generation of biomedical research.
See full Parse Biosciences company page
